Exenatide

Byetta (twice-daily), Bydureon and Bydureon BCise (once-weekly extended-release), exendin-4 (the natural peptide it copies), AC2993

Metabolic & weight

Awaiting medical reviewEN ES DE FR PT ZH+ Follow for updates

Note on this profile. Exenatide is an approved prescription medicine for type 2 diabetes, not a research-only compound. This page explains the published science, including its investigation in Parkinson's disease. Use outside a prescription carries real risks discussed below.

Summary

Class: GLP-1 receptor agonist; synthetic copy of exendin-4, a 39-amino-acid peptide first isolated from the saliva of the Gila monster lizard. About 53% identical to human GLP-1
Mechanism: Activates the GLP-1 receptor: more insulin when glucose is high, less glucagon, slower stomach emptying, less appetite
Routes studied: Subcutaneous: twice daily (Byetta) or once weekly as a microsphere depot (Bydureon); intravenous and intranasal in research only
Dose range reported: Approved: Byetta 5 µg twice daily for ≥1 month, then 10 µg twice daily, within 60 minutes before the two main meals; Bydureon 2 mg once weekly. Parkinson's trials used Bydureon 2 mg weekly off-label
Half-life: ~2.4 hours (immediate release). The weekly form releases slowly from degradable microspheres; steady state takes 6–7 weeks and drug persists for ~10 weeks after the last dose
Storage: Unopened pens/kits: refrigerate. Byetta after first use: room temperature or fridge, discard after 30 days. Bydureon BCise: may be kept at room temperature up to 4 weeks
Regulatory status: Approved medicine for type 2 diabetes (US, EU, UK, AU, ZA). Some presentations have been discontinued commercially †

Doses are as reported in studies or by the community — never recommendations.

1What it is

Exenatide was the first GLP-1 receptor to reach the market. It is a synthetic version of exendin-4, a peptide found in the venom-containing saliva of the Gila monster (Heloderma suspectum), a lizard that eats a few large meals a year. Exendin-4 happens to activate the human GLP-1 receptor and, unlike human GLP-1, is resistant to the enzyme DPP-4 that destroys GLP-1 within minutes. That resistance is why it could be developed as a drug.

Byetta (twice-daily injection) was approved in the US in 2005, developed by Amylin Pharmaceuticals and Eli Lilly, later owned by AstraZeneca. Bydureon, a once-weekly version that encases exenatide in slowly dissolving polymer microspheres, followed in 2011–2012. Both have been overtaken by newer, longer-acting agonists (liraglutide, dulaglutide, semaglutide, tirzepatide), and AstraZeneca has withdrawn some presentations from some markets in the 2020s †.

Exenatide has a second life in neurology: it is the GLP-1 agonist most studied in Parkinson's disease.

2How it's thought to work

Exenatide binds and activates the GLP-1 receptor on pancreatic beta cells, in the gut, and in the brain:

Pancreas. glucose-dependent insulin release and suppression of glucagon; because the effect is glucose-dependent, hypoglycaemia is uncommon unless combined with insulin or sulfonylureas.

Stomach. markedly slowed gastric emptying, which is why the twice-daily form is timed before meals and lowers post-meal glucose spikes.

Brain. reduced appetite via hypothalamic and brainstem GLP-1 receptors.

Neuroprotection hypothesis. GLP-1 receptors are expressed on neurons; in rodent models exenatide reduces inflammation, improves insulin signalling in the brain and protects dopamine-producing cells. This is the rationale for the Parkinson's trials.

A GLP-1 receptor agonist copied from Gila monster venom, which resists the enzyme that destroys human GLP-1 in minutes. More insulin after a meal, slower stomach emptying, less appetite.Schematic — not to scale

3What the research shows

Glucose control in type 2 diabetes

The AMIGO programme (three 30-week placebo-controlled trials on top of metformin, a sulfonylurea or both) showed HbA1c reductions of roughly 0.8–0.9 percentage points with 10 µg twice daily, with modest weight loss of 1.5–3 kg (Buse 2004; DeFronzo 2005; Kendall 2005 — all Diabetes Care). The DURATION trials showed the weekly form lowers HbA1c more than the twice-daily form (about −1.9 vs −1.5 points in DURATION-1; Drucker 2008, Lancet), with less nausea but more injection-site reactions. [2][3][4]

Graded A (neutral)

Cardiovascular outcomes

EXSCEL (n≈14,750, type 2 diabetes, ~73% with prior cardiovascular disease) found weekly exenatide did not increase and did not significantly reduce major adverse cardiovascular events over a median 3.2 years (hazard ratio 0.91, just missing superiority; Holman 2017, NEJM). All-cause mortality was numerically lower. This is a safety result rather than a benefit result, in contrast to liraglutide (LEADER), semaglutide (SUSTAIN-6, SELECT) and dulaglutide (REWIND). [5]

Weight loss in people without diabetes

Small trials in obesity without diabetes report weight loss in the 2–5 kg range, less than with newer (e.g. Rosenstock 2010, Diabetes Care). Exenatide is not approved for weight management anywhere.

Graded A (mixed, latest result negative)

Parkinson's disease

A 48-week single-centre, placebo-controlled trial of Bydureon 2 mg weekly in 62 people with moderate Parkinson's reported better motor scores off medication at 60 weeks (a 3.5-point advantage on the MDS-UPDRS part 3; Athauda 2017, Lancet). This generated considerable excitement. The follow-up Exenatide-PD3 trial, a 96-week multicentre phase 3 in 194 people, reported in 2025 that exenatide did not slow progression on the same primary endpoint or on secondary measures (Vijiaratnam 2025, Lancet). The current reading is that exenatide does not modify Parkinson's disease course at the dose tested, although other GLP-1 agonists with better brain penetration are still being studied (see lixisenatide, profile 63). [6][7]

Graded B/C

Other neurological and psychiatric uses

Small human studies in Alzheimer's disease (negative pilot), alcohol use disorder (a Danish trial found no overall reduction in heavy drinking, with a possible signal in people with obesity; Klausen 2022, JCI Insight), and cocaine use are exploratory. Rodent data on neuroprotection are extensive but did not translate in PD3. [8]

4Reported side effects and interactions

Literature-reported

Literature (common). nausea (around 40–50% with twice-daily dosing early on, falling over weeks; lower with weekly form), vomiting, diarrhoea, constipation, dyspepsia, headache, reduced appetite. Weekly form: injection-site nodules (small, usually harmless lumps where microspheres sit) in a large share of users, itching and redness.

Serious / label warnings. acute pancreatitis including rare haemorrhagic or necrotising cases, with a causal link debated; acute kidney injury, mostly from dehydration after vomiting; serious hypersensitivity (anaphylaxis, angioedema) rarely; boxed warning on the weekly form for thyroid C-cell tumours seen in rodents, contraindicated in personal or family history of medullary thyroid carcinoma or MEN2; gallbladder disease; anti-exenatide antibodies develop in many users and at high titre can reduce glucose-lowering effect. Twice-daily form is not recommended with severe kidney impairment (creatinine clearance <30 ml/min) or end-stage kidney disease.

Community-reported

little community use outside diabetes because of twice-daily dosing and nausea; some interest after the 2017 Parkinson's result.

Interactions. hypoglycaemia with insulin or sulfonylureas (the label advises reducing sulfonylurea dose); slowed absorption of oral drugs, so medicines that need rapid absorption (e.g. some antibiotics, oral contraceptives) are advised to be taken at least 1 hour before the injection; warfarin INR changes have been reported. Not for use in pregnancy or type 1 diabetes.

Markers researchers commonly monitor

Following the approved-label monitoring and trial protocols:

Marker	Why it's watched
HbA1c and fasting glucose	the primary efficacy measure; also for hypoglycaemia when combined with insulin or sulfonylureas.
eGFR and creatinine	kidney injury from dehydration is a labelled risk; the twice-daily form is not recommended below creatinine clearance 30 ml/min.
Lipase/amylase	only if persistent abdominal pain occurs; not routine.
Weight and waist circumference	a secondary effect that is modest with this agonist.
Injection-site inspection	nodules with the weekly form are common and usually resolve; an unusual growing, hot or draining lump needs a clinician.
Heart rate	GLP-1 agonists raise resting heart rate by a few beats per minute.
Calcitonin	only on clinician advice, relating to the rodent thyroid C-cell warning.

Free for everyone. Safety information is never behind a paywall.

5Reconstitution and handling

Byetta is a pre-filled pen needing no . The original Bydureon kit required mixing a vial of microsphere powder with a immediately before injection and injecting straight away, because the suspension settles; the later BCise autoinjector is pre-mixed and needs vigorous shaking (not swirling) for about 15 seconds until uniformly cloudy. These are not research peptides and the standard calculator does not apply; follow the product instructions. (immediate-release vials only; doses are in micrograms)

Open in calculator, pre-loaded →

6Commonly studied alongside

Metformin, basal insulin and sulfonylureas (diabetes trials). As a comparator to liraglutide, dulaglutide and semaglutide. Lixisenatide and semaglutide in the Parkinson's/neurodegeneration field. Pramlintide was studied alongside it in some early Amylin Pharmaceuticals work.

Informational cross-links. Not stack recommendations.

7Regulatory status by region

Region	Status (checked —)
United States	FDA-approved for type 2 diabetes (Byetta 2005; Bydureon 2012; Bydureon BCise 2017). Byetta and Bydureon presentations reported discontinued by the manufacturer in the 2020s †
European Union	EMA-authorised (Byetta 2006; Bydureon 2011) for type 2 diabetes; some presentations withdrawn commercially †
United Kingdom	MHRA-licensed; prescription-only; NICE includes GLP-1 agonists in type 2 diabetes pathways
Australia	TGA-approved; PBS-listed historically †
South Africa	SAHPRA-registered; prescription-only
Sport	Not prohibited by WADA (GLP-1 agonists not listed as of 2026 †)

8Open questions

Why did the promising 2017 Parkinson's result not replicate in the larger phase 3? Dose, brain penetration, patient selection and chance are all candidates.
Whether exenatide's neutral cardiovascular result reflects the molecule or the trial population.
Long-term significance of anti-drug antibodies, which are more common with exenatide than with human-sequence analogues.

9References

1Eng J et al. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem. PubMed
2Buse JB et al. (2004). Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. PubMed · DOI
3DeFronzo RA et al. (2005). Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. PubMed · DOI
4Drucker DJ et al. (2008). Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study (DURATION-1). Lancet. PubMed
5Holman RR et al. (2017). Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (EXSCEL). NEJM. PubMed · DOI
6Athauda D et al. (2017). Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. PubMed · DOI
7Vijiaratnam N et al. (2025). Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet. PubMed · DOI
8Klausen MK et al. (2022). Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. PubMed · DOI
9AstraZeneca. Byetta and Bydureon BCise prescribing information (current labels). PubMed

References are being resolved to PubMed/DOI identifiers; links search PubMed for the citation until then.

† Being confirmed by our reviewers against current sources.

10Community

forum threads →

community protocols include this →

Threads and protocols are visible to members. Joining is free.

Self-reported side effects Phase 2

Not enough data yet. 0 of the 50 members needed have logged this compound for 4+ weeks. We don't show anything below 50, so no one can be identified.

11Page history

26 Oct 2026Profile published — awaiting medical review

Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.